Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jin Medical International (ZJYL) Common Equity (2022 - 2025)

Jin Medical International's Common Equity history spans 3 years, with the latest figure at $29.6 million for Q3 2025.

  • For Q3 2025, Common Equity changed N/A year-over-year to $29.6 million; the TTM value through Sep 2025 reached $29.6 million, changed N/A, while the annual FY2025 figure was $29.6 million, N/A changed from the prior year.
  • Common Equity for Q3 2025 was $29.6 million at Jin Medical International, up from $24.0 million in the prior quarter.
  • Across five years, Common Equity topped out at $29.6 million in Q3 2025 and bottomed at $15.2 million in Q3 2022.
  • The 3-year median for Common Equity is $24.0 million (2023), against an average of $23.0 million.
  • The largest YoY upside for Common Equity was 57.39% in 2023 against a maximum downside of 57.39% in 2023.
  • A 3-year view of Common Equity shows it stood at $15.2 million in 2022, then surged by 57.39% to $24.0 million in 2023, then rose by 23.6% to $29.6 million in 2025.
  • Per Business Quant, the three most recent readings for ZJYL's Common Equity are $29.6 million (Q3 2025), $24.0 million (Q3 2023), and $15.2 million (Q3 2022).